z-logo
open-access-imgOpen Access
Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance
Author(s) -
Horacio A. Duarte,
Nuttada Panpradist,
Ingrid A. Beck,
Barry R. Lutz,
James J. Lai,
Ruth Kanthula,
Rami Kantor,
Anubhav Tripathi,
Shanmugam Saravanan,
Iain J. MacLeod,
Michael H. Chung,
Guoqing Zhang,
Chunfu Yang,
Lisa M. Frenkel
Publication year - 2017
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jix413
Subject(s) - point of care testing , human immunodeficiency virus (hiv) , virology , point of care , polymerase chain reaction , medicine , drug resistance , loop mediated isothermal amplification , point mutation , nucleic acid , immunology , biology , pathology , genetics , mutation , dna , gene
Healthcare delivery has advanced due to the implementation of point-of-care testing, which is often performed within minutes to hours in minimally equipped laboratories or at home. Technologic advances are leading to point-of-care kits that incorporate nucleic acid-based assays, including polymerase chain reaction, isothermal amplification, ligation, and hybridization reactions. As a limited number of single-nucleotide polymorphisms are associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assays to detect these mutations have been developed. Early versions of these assays have been used in research. This review summarizes the principles underlying each assay and discusses strategic needs for their incorporation into the management of HIV infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom